4Gen Ventures announces 2020 launch date

Latest articles

Ovarian aging – it’s time to menopause for thought

It's World Menopause Day – time to focus on the future of ovarian longevity, not dwell in the present. World Menopause Day is held every...

At-home blood test powers personalised longevity advice

AgeRate develops proprietary DNA methylation clock and mobile app solution to offer users personalised longevity support. Canadian startup AgeRate is aiming to shake up the...

Researchers find warning signs for dementia in the blood

Levels of certain microRNAs indicate risk for cognitive decline. Researchers at the DZNE and the University Medical Center Göttingen (UMG) have identified molecules in the...

VIDEO: The Science of Ovarian Longevity

Instead of papering over the cracks of declining fertility and the effects of menopause, what else can we do to help the longevity of...

Most read

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Editor's picks

Ovarian aging – it’s time to menopause for thought

It's World Menopause Day – time to focus on the future of ovarian longevity, not dwell in the present. World Menopause Day is held every...

At-home blood test powers personalised longevity advice

AgeRate develops proprietary DNA methylation clock and mobile app solution to offer users personalised longevity support. Canadian startup AgeRate is aiming to shake up the...

Researchers find warning signs for dementia in the blood

Levels of certain microRNAs indicate risk for cognitive decline. Researchers at the DZNE and the University Medical Center Göttingen (UMG) have identified molecules in the...

Click the globe for translations.

New Age-tech fund will capitalise upon trend towards “multi-generational living”

4Gen Ventures, a new venture capital fund entering the Agetech space, plans to begin investing in early 2020, founder Dominic Endicott has revealed to Longevity.Technology. The funding round’s raise is targeting between £50-100m, according to Endicott, and will include contributions from a broad-range of corporate and institutional investors. The fund will start putting its money to work once it has reached £50m in commitments, which is slated to happen by the end of this year. 

The news comes at a time of increasing interest in the Age-tech market from angel-investors and VCs, who see great opportunity in companies serving the later-life needs of aging western populations. 

“By 2035, there will be 78.0 million people 65 years and older compared to 76.7 million (previously 76.4 million) under the age of 18,” the US Census Bureau declared this year. 4Gen plans to take full advantage of this tipping point, with its founders projecting a potential $30tn global spend in the market by 2025.

Mr Endicott forecasts that the broad appeal of Agetech will see investment into new VC funds not just from the traditional institutional sources, like pension funds or banks — but from a broader range of corporate investors. 

“In a perfect world, we would love to have partnerships and investment from a broad range of verticals,” says Mr Endicott. “We would love to work with financial services companies, but we’d also love to work with real estate, utilities, food, retail and transport. It’s not just their lender’s capital that we want to harness, but their expertise, as well. This isn’t just an investment opportunity, but a very broad social shift as well.”

4Gen takes its name from an anticipation of this shift, with rising costs in housing and social care causing families in the US & UK to increasingly consider “multi-generational living,” — cohabiting or living together in close neighbourhoods across four generations. 

Mr Endicott says the fund will be targeting the US and UK market, where he and co-founder Alasdair Greig have the most experience. It will also be run in partnership with Northstar ventures, a fund that has been investing in UK tech businesses since 2004. Mr Endicott enters the Age-tech funding space with his own experience, having sold GreatCall to BestBuy in 2018 for $800m. The Age-tech company, which Mr Endicott invested in when he was a General Partner at Nauta Capital, provides health and safety services for older adults through mobile devices and wearables. 

Ben Turner
Staff Writer Ben Turner is a writer and journalist based in London. He graduated in 2015 with a Master’s degree in Physics. He is particularly interested in the translation of early scientific discoveries into cutting-edge tech.

Most popular

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...

Related articles

$70m collaboration to redefine aging research

Astera Institute and Buck Institute announce $70 million collaboration to redefine the field of research on aging. The Buck Institute for Research on Aging and...

Rejuveron leads €15.7m series B in Rejuvenate Biomed

Investment in Rejuvenate Biomed set to accelerate clinical development of its sarcopenia treatment for healthy aging. Rejuveron Life Sciences, a Zürich-based biotechnology company developing therapies...

Maximon launches 100 million Longevity Co-Investment Fund

The Longevity Co-Investment Fund finances longevity-focussed start-up companies launched by company-builder Maximon. Switzerland-based Maximon has announced the launch of its Longevity Co-Investment Fund (LCIF),...

NOVOS – from stealth to oversubscription and beyond

NOVOS is dreaming big to improve health, quality of life and lifespan all at the same time. Last week we covered NOVOS' $3.15 million pre-seed...

Longevity start-up NOVOS closes $3.15m financing round

Successful round for NOVOS sees longevity supplement company raise $3.15 million pre-seed to further its aim to extend healthy human lifespan with science-based supplements. NOVOS,...